All News
Autoimmune Risk of Death Up during COVID
A population-based study in the UK shows that patients with rare autoimmune rheumatic diseases (RAIRD) were 44% more likely to die during the 2020 COVID-19 pandemic (March - April) compared to either the general population or their pre-COVID risk.
Read Article
DMARD Dropouts During COVID-19
A full year from the onset of the SARS-COV-2 pandemic, rheumatologists are still seeing the consequences of COVID, with many patients avoiding usual care, follow-up visits, routine lab testing and with many self-stopping their antirheumatic meds, because it seemed like the right thing to do.
Read Article
RheumNow Podcast – Mistakes with Steroids
Dr Jack Cush gives his spin on this week's RheumNews and Rheum Research from RheumNow.com.
Read Article
Rheumatology Care Derailed by COVID-19
A survey study from the ArthritisPower PPRN or CreakyJoints database shows that during the COVID-19 pandemic patient care was substantially affected in unforeseen ways.
Read Article
Reactogenicity Following mRNA COVID-19 Vaccines
JAMA has published the real-world reporting of mRNA vaccine side effects (reactogenicity) gathered from CDC V-safe Surveillance system and shows that local and systemic reactions were often mild and transient and most commonly seen during the first day following their second dose.
Read Article
HLA B27 Iritis - RNL 2021 Highlights
The Spondyloarthritis Advances pod presented during the RheumNow Live 2021 conference featured three speakers, including an excellent lecture by Dr. Robert Wang, ophthalmology, on HLA B27 iritis and practical tips for rheumatologists.
Read Article
Serious Infections Still Common in Vasculitis
Serious infections occurred more frequently among patients with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis who were given induction therapy with cyclophosphamide compared with rituximab (Rituxan), Greek researchers found.
Read Article
Liver Management in Rheumatoid Arthritis - RNL2021 Highlight
While rheumatoid arthritis (RA) is not known to affect the liver directly, underlying liver disease and treatment-related effects on the liver can often become an obstacle in the management of many RA patients. In his Sunday presentation at RNL2021, Dr.
Read Article
Rheumatic Patients Are at Risk for COVID Death
Patients with rheumatic diseases who developed COVID-19 were at increased likelihood of death, with risk factors similar to those seen in the general population but also because of factors specific to their underlying disease and its treatment, analysis of data from an international registry foun
Read Article
RheumNow Podcast – Listener Questions (3.12.2021)
Dr Jack Cush reviews the news, Journal reports, CDC guidelines and viewer questions from the last week on RheumNow.com
Read Article
Low Anaphylaxis Risk with COVID mRNA Vaccines
JAMA reports a safety survey of hospital employees showing that the risk of anaphylaxis from mRNA vaccines is 2.47 per 10,000 individuals.
Read Article
COVID-19-Related Deaths in Rheumatic Disease Patients
There is a growing body of evidence regarding COVID-19 outcomes (including death) in rheumatic disease patients; analysis of a German registry shows that poor control, rituximab, sulfasalazine and other immunosuppressives could be risk factors for COVID-related death.
Read Article
Comparison of Three Coronavirus Vaccines
On Feb. 27, the Food and Drug Administration announced it has issued an emergency use authorization for Johnson & Johnson’s one-dose Covid vaccine, making it the third COVID-19 vaccine to be commercially available. We've compiled a comparison table and some key information relevant to your delivering patient guidance henceforth.
Read Article
CDC: Interim Guidance for COVID Vaccinated People
Among 330 million Americans, roughly 32.1 million have been fully vaccinated and 61.1 million have received at least one dose of a COVID-19 vaccine (as of March 8th).
Read Article
RheumNow Podcast – Pounds of Prevention (3.5.2021)
Dr. Jack Cush reviews and discusses nearly a dozen news reports and journal articles from the past week on RheumNow.com.
Read Article
Baricitinib Therapy in Covid-19 Pneumonia
The NEJM has published the results of the ACCT-2 Study, a double-blind, randomized, placebo-controlled trial evaluating baricitinib, an inhibitor of Janus kinase 1 (JAK1) and JAK2, plus remdesivir in hospitalized adults with Covid-19. The primary outcome was the time to recovery.
Read Article
ACR Promotes New COVID-19 Vaccine Clinical Guidance for Rheumatic Patients
The American College of Rheumatology has published a draft guidance on the use of COVID-19 vaccination in rheumatic disease and musculoskeletal disease patients, based on the efforts of the North American Task force. The document provides guidance to rheumatology providers on the use of the COVID-19 vaccine and the associated management of RMD patients around the time of vaccination. Here is a summary of the recommendations.
Read Article
Comorbidity and Drugs Drive COVID-19 Severity and Survival in Rheumatic Disease
While comorbidities are associated with severe COVID-19 infection, it appears they also influence severity and survival in rheumatic disease (RMD), according to a a French cohort study,
Read Article
Links:
Links:
